Despite its remarkable impact on the therapeutic approach in lung cancer, targeting KRAS-mutant lung cancer cells remains a challenge; however, KRAS-G12C–specific inhibitors at the clinical trial stage are forthcoming (26, 27). Here, KRAS is linked to lung carcinoma.